# A New Startup Is Building AI-Powered Labs to Speed Up Drug Discovery
A recently launched biotech technology company has raised $215 million to build a network of automated laboratories in the United States. Its mission is simple but ambitious: combine robots, artificial intelligence, and human chemists to help pharmaceutical and biotech teams discover new medicines faster than ever before.
## What Does This Company Do?
The company, based in South San Francisco, describes itself as a chemistry-focused contract research organization — a specialized lab partner that designs, builds, and runs experiments for other companies. Rather than developing its own drugs, it creates the infrastructure that researchers need to test molecular compounds quickly and reliably.
At the heart of its approach is a feedback loop: run an experiment, learn from the results, then use those lessons to make the next experiment smarter. The company believes that by generating large amounts of real-world laboratory data, it can train more powerful AI models that will, in turn, accelerate scientific discovery across the entire industry.
## Why U.S.-Based Chemistry Services Matter
The company pointed to a growing concern in the biotech world — many drug discovery programs depend on overseas laboratories for critical chemistry work. While those partners can be fast and skilled, there are risks around intellectual property protection, supply chain reliability, and national security.
A legislative framework introduced in late 2025 created new guidelines for federal funding and procurement related to foreign biotechnology partners, further highlighting the need for domestic alternatives. This new startup aims to fill that gap by offering high-quality chemistry services within the United States, giving researchers more control over sensitive projects and their proprietary data.
## Who Is Behind the Company?
The founding team brings together deep expertise across artificial intelligence, drug development, data engineering, and healthcare.
The CEO previously served in a senior science and product leadership role at a major AI research company. The Chief Scientific Officer spent years leading medicinal chemistry efforts at a biotech firm. The Chief Technology Officer was a key researcher at a leading AI lab and helped build one of the most influential AI research teams in the world.
Other founding members include a former White House chief data scientist and a healthcare startup executive. Early team additions also include robotics engineers from well-known automation and AI companies, as well as scientists from established pharmaceutical and national research organizations.
## How Will It Use the Funding?
The $215 million round was led by a prominent venture capital firm and supported by a long list of investors from the technology, healthcare, and finance sectors. Several well-known tech leaders also contributed as private investors, including executives from major AI companies, robotics firms, and social media platforms.
The company plans to use the capital to build out its first fully automated laboratories, hire top scientists and engineers, and begin offering its initial services to partner organizations. Early offerings will focus on creating variations of molecules that researchers can compare as they search for promising drug candidates.
## FAQ
**What kind of company is this?**
It is a startup that builds automated chemistry labs powered by robotics and artificial intelligence, offering contract research services to biotech and pharmaceutical companies.
**Does it develop its own drugs?**
No. The company explicitly states it does not have its own drug pipeline. It provides the tools, labs, and data infrastructure that other organizations use to advance their own discovery programs.
**Why is it based in the United States?**
It aims to give researchers a trusted domestic partner for chemistry services, addressing concerns about intellectual property protection, data security, and supply chain resilience.
**How does AI fit into its work?**
AI models are trained on data generated from physical experiments run in its automated labs. The insights from those models help guide future experiments, creating a cycle of continuous improvement.
**What is its first service?**
Its initial offering is lead optimization analog synthesis — creating small variations of molecules so researchers can compare and evaluate them as they hunt for drug candidates.
**Who are its investors?**
Its funding round was led by a major venture capital firm and included participation from dozens of well-known technology and life science investors, along with several prominent tech industry figures as angel investors.
## Conclusion
This new company represents a bold bet on the future of drug discovery. By combining robotics, artificial intelligence, and real-world chemistry in fully automated U.S.-based labs, it hopes to give researchers the speed, quality, and security they need to bring new treatments to patients faster. If its approach works, it could reshape how the pharmaceutical industry thinks about the early stages of medicine development.
Thank you for reading
